内容概要：烘焙酶制剂是一类通过生物技术提取的天然蛋白质催化剂，专用于改善烘焙食品的品质、加 工性能及营养价值。其通过分解面团中的淀粉、蛋白质或纤维素等成分，增强面团延展性、提升发酵效 率、延缓老化并优化成品质地。近年来，在烘焙食品市场规模持续扩大和消费升级双重驱动下，中国烘 焙酶制剂行业迎来了快速发展期。随着消费者对健康、功能性烘焙产品的需求日益增长，特别是低糖、 高纤维等健康概念的普及，功能性酶制剂市场需求呈现爆发式增长态势。2024年我国烘培酶制剂行业市 场规模约21.5亿元，同比增长15%。在技术创新持续突破、应用场景不断拓展的推动下，预计2025年行 业规模将进一步增长至24.8亿元，行业发展前景广阔。 上市企业：安琪酵母（600298.SH）、蔚蓝生物（603739.SH）、溢多利（300381.SZ）、安迪苏 （600299.SH） 相关企业：南宁东恒华道生物科技有限责任公司、山东隆科特酶制剂有限公司、武汉新华扬生物股份有 限公司、无锡市雪梅酶制剂科技有限公司、江苏博立生物制品有限公司、山东龙力生物科技股份有限公 司 关键词：烘培酶制剂、烘培食品、烘培酶制剂产业链、烘培酶制剂发展现状、烘培酶市场规 ...

【全新修订】：2025年6月 【出版机构】：中智信投研究网 全球与中国非淀粉多糖酶市场规模预测及前景战略研究报告2025-2031年 【内容部分有删减·详细可参中智信投研究网出版完整信息！】 【免费售后 服务一年，具体内容及订购流程欢迎咨询客服人员 】 报告目录 1 非淀粉多糖酶市场概述 1.1 产品定义及统计范围 1.2 按照不同产品类型，非淀粉多糖酶主要可以分为如下几个类别 1.2.1 全球不同产品类型非淀粉多糖酶销售额增长趋势2020 VS 2024 VS 2031 5.7.1 Amano Enzyme Incorporated基本信息、非淀粉多糖酶生产基地、销售区域、竞争对手及市场地位 5.7.2 Amano Enzyme Incorporated 非淀粉多糖酶产品规格、参数及市场应用 5.7.3 Amano Enzyme Incorporated 非淀粉多糖酶销量、收入、价格及毛利率（2020-2025） 5.7.4 Amano Enzyme Incorporated公司简介及主要业务 5.7.5 Amano Enzyme Incorporated企业最新动态 5.8 BASF 5.8.1 BASF ...

Dyadic International (DYAI) Q1 2025 Earnings Call May 14, 2025 05:00 PM ET Company Participants Ping Rawson - Chief Financial OfficerMark Emalfarb - President and Chief Executive OfficerJoseph Hazelton - Chief Operating OfficerPaul Rosenbaum - CEOTony Bowers - Director of Corporate sales Conference Call Participants John Vandermosten - Senior AnalystDick Williams - Analyst Operator Evening, and welcome to the Dyadic International First Quarter twenty twenty five Financial Results Conference Call. Currently, ...

Core Insights - In 2024, the company achieved operating revenue of 1.32 billion yuan, a year-on-year increase of 10.16%, while net profit attributable to shareholders was 63 million yuan, a decline of 22.39% [1] - The decline in profit is attributed to increased depreciation expenses after the completion of the animal health industrial park, a 17.49% rise in management expenses, and a 46.48% increase in financial expenses due to interest expenses being recognized as costs [1] Enzyme Business - The enzyme business generated revenue of 505 million yuan in 2024, a year-on-year growth of 14.34%, becoming the main driver of the company's revenue growth [2] - The gross profit margin reached 63.69%, an increase of 2.89 percentage points, driven by continuous investment in technological innovation and optimization of production processes [2] - The company is expanding into various fields including industrial enzymes, food enzymes, and pharmaceutical enzymes, and has established an AI technology development laboratory to enhance R&D efficiency [2] Animal Health Products - Revenue from the animal health products business was 308 million yuan in 2024, a slight increase of 3.56%, but the gross profit margin fell to 33.51%, down 8.23 percentage points [3] - The decline in gross profit margin is primarily due to increased depreciation after the industrial park's completion, but long-term benefits are expected from improved product structure and quality [3] - The company plans to focus on biological products, particularly pig vaccines and imported generics, while also expanding into the pet medicine sector [3] Capacity and R&D Investment - With the increase in new capacity utilization and the gradual release of new products, the profitability of the animal health business is expected to recover [4] - The company invested 118 million yuan in R&D in 2024, a year-on-year increase of 6.81%, accounting for 8.95% of revenue, with 266 R&D personnel [4] - The company has established six technology centers and two key laboratories, with major projects expected to be operational by 2025, laying a foundation for future growth [4] Profit Forecast and Investment Recommendation - The expected EPS for 2025-2027 is projected to be 0.44 yuan, 0.51 yuan, and 0.60 yuan, corresponding to dynamic PE ratios of 29, 24, and 21 times, respectively, maintaining a "hold" rating [4]

Investment Rating - The report maintains a "Recommended" rating for the company, indicating a potential upside of over 15% relative to the benchmark index [6][8]. Core Views - The company experienced short-term pressure on performance, with a 10.16% year-on-year revenue growth to 1.32 billion yuan in 2024, but a 22.39% decline in net profit attributable to shareholders [3][4]. - The company is focusing on innovation and increasing R&D investment, which reached 118 million yuan in 2024, accounting for 8.95% of revenue, and is expected to drive long-term growth [5][6]. - The company has completed its capacity layout, enhancing multi-business synergy, with several projects operational by the end of 2024 [5]. Financial Performance Summary - In 2024, the company achieved revenue of 1.32 billion yuan, with a net profit of 63 million yuan, reflecting a decline in profitability due to increased competition and higher depreciation costs [3][4]. - For Q1 2025, the company reported revenue of 310 million yuan, a year-on-year increase of 8.16%, but a 24.73% decline in net profit [3][4]. - The company forecasts revenue growth rates of 10.2%, 8.4%, 8.9%, and 9.4% for the years 2024 to 2027, respectively [7][11]. Business Segment Performance - In 2024, the enzyme preparation segment generated 505 million yuan, the micro-ecology segment 193 million yuan, and the animal health products segment 308 million yuan, with respective gross margins of 63.69%, 37.29%, and 33.51% [4]. - For Q1 2025, the enzyme preparation segment achieved revenue of 120 million yuan, with a gross margin of 44.36% [4]. R&D and Innovation - The company has applied for 81 invention patents related to probiotics and has published 32 articles, enhancing its competitive strength in nutrition and health-related businesses [5][6]. - The integration of AI technology is expected to further strengthen the company's capabilities in product innovation and application design [5]. Future Earnings Forecast - The company is projected to achieve net profits of 74 million yuan in 2025, 81 million yuan in 2026, and 90 million yuan in 2027, with corresponding EPS of 0.29, 0.32, and 0.35 yuan [6][7].

报告期内，公司积极探索AI技术与生物制造的深度融合，成立AI技术开发及应用实验室，稳步推进AI 技术在酶蛋白功能特性优化、酶蛋白质高效表达的代谢网络调控及菌种智能发酵优化等领域的探索与实 践。 在完善动物大健康系统方面，蔚蓝生物构建产业+服务的综合赋能平台，提供涵盖动物营养、健康养 殖、动物疫病的系统化解决方案。特别是公司VLAND-PCP定制酶方案(基于饲料酶应用大数据系统的精 准定制平台)已积累上百种饲料原料用酶数据库并持续更新，已获得众多大客户的认可。 中证报中证网讯(记者张鹏飞)蔚蓝生物（603739）4月25日晚间发布2024年度报告。报告显示，公司全 年实现营业收入13.21亿元，同比增长10.16%；实现归属于上市公司股东的净利润6263.75万元，同比下 降22.39%。公司全年研发投入达1.18亿元，占营收比例8.95%，通过技术创新与全球化布局，公司夯实 核心竞争力，推动长期可持续发展。 酶制剂被誉为工业生物技术领域的"芯片"，其中表达系统的构建是微生物生产菌株开发的核心，也是产 品从实验室迈向大规模生产的关键。目前，蔚蓝生物已构建里氏木霉、毕赤酵母、黑曲霉、芽孢杆菌四 大高效蛋白质表达系 ...